share_log

Credit Suisse Reiterates Outperform on Pyxis Oncology, Maintains $14 Price Target

Benzinga ·  Mar 23, 2023 08:17

Credit Suisse analyst Tiago Fauth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment